SGLT-2 Inhibitors
Showing 1 - 25 of >10,000
Polycystic Ovary Syndrome Trial (SGLT2 inhibitors combined with metformin, Placebo combined with metformin)
Not yet recruiting
- Polycystic Ovary Syndrome
- SGLT2 inhibitors combined with metformin
- Placebo combined with metformin
- (no location specified)
Jul 21, 2023
The Triglyceride/Glucose Index and SGLT-2 Inhibitors
Recruiting
- Metabolic Disease
- Diabetes
- SGLT-2 inhibitors
-
Samsun, İlkadım, TurkeySamsun Education and Research Hospital
Jun 14, 2023
Acute Kidney Injury Trial (SGLT2 inhibitor)
Not yet recruiting
- Acute Kidney Injury
- SGLT2 inhibitor
- (no location specified)
Nov 3, 2023
SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac
Recruiting
- Coronary Artery Disease
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
-
Shah Alam, Selangor, MalaysiaInstitute for Clinical Research, National Institutes of Health,
Nov 9, 2023
Heart Failure Acute, Ventilator Lung Trial in Taipei (SGLT2 inhibitor)
Recruiting
- Heart Failure Acute
- Ventilator Lung
- SGLT2 inhibitor
-
Taipei, TaiwanNational Taiwan University Hospital
Nov 16, 2023
Type 2 Diabetes Trial (SGLT2 inhibitor)
Not yet recruiting
- Type 2 Diabetes Mellitus
- SGLT2 inhibitor
- (no location specified)
Feb 12, 2023
SLE, Lupus Nephritis, SGLT2 Inhibitors Trial in Mansoura (dapagliflozin, )
Active, not recruiting
- SLE
- +2 more
- dapagliflozin
- placebo
-
Mansoura, EgyptUrology and Nephrology Center
Feb 18, 2023
Prediabetic State, Impaired Fasting Glucose, Impaired Glucose Tolerance Trial in Beijing (Dapagliflozin 10mg Tab, lifestyle
Not yet recruiting
- Prediabetic State
- +2 more
- Dapagliflozin 10mg Tab
- lifestyle interventions
-
Beijing, Beijing, ChinaPeking University Third Hospital
Jun 19, 2023
Type 2 Diabetes, Type 1 Diabetes Trial in San Antonio (Empagliflozin 25 MG, Placebo)
Not yet recruiting
- Type 2 Diabetes
- Type 1 Diabetes
- Empagliflozin 25 MG
- Placebo
-
San Antonio, TexasTexas Diabetes Institute/UH
Jul 31, 2023
SGLT2 INHIBITORS, Lupus Nephritis, BMD Trial in Mansoura (Dapagliflozin tablet, )
Active, not recruiting
- SGLT2 INHIBITORS
- +2 more
- Dapagliflozin tablet
- placebo
-
Mansoura, EgyptUrology and Nephrology Center
Jan 19, 2023
Heart Failure, Hypertension, Left Ventricle Remodeling Trial (Empagliflozin 10 MG, Placebo)
Not yet recruiting
- Heart Failure
- +3 more
- Empagliflozin 10 MG
- Placebo
- (no location specified)
Sep 20, 2023
Obesity, Weight Loss Trial in Birmingham (Empagliflozin Arm, Control Arm, Exercise capacity VO2 maximum determination)
Not yet recruiting
- Obesity
- Weight Loss
- Empagliflozin Arm
- +3 more
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
May 22, 2023
Heart Failure Trial in Denmark (Digital letter)
Recruiting
- Heart Failure
- Digital letter
-
Copenhagen, Denmark
- +4 more
Jun 5, 2023
Cancers Among Diabetics ,Observational Study
Enrolling by invitation
- Cancer
- +3 more
- interleukin 6
-
Riyadh, N/A (Non-US), Saudi Arabiaministry of health , First health cluster , Riaydh
Oct 28, 2022
SGLT-2 Inhibitors in the Treatment of Ascites
Recruiting
- Ascites Hepatic
- +2 more
- SGLT2 inhibitor
-
Palermo, Italy
- +1 more
Aug 11, 2023
Cystinuria Trial in San Francisco (Dapagliflozin)
Recruiting
- Cystinuria
-
San Francisco, CaliforniaUniversity of California, San Francisco
Oct 4, 2022
SGLT2 for Heart Failure in CHD Patients
Not yet recruiting
- Heart Failure
-
Nice, FranceUniversity hospital of Nice
Jun 7, 2023
SGLT2 Inhibition in Heart Failure
Recruiting
- Heart Failure
- Sodium-glucose cotransporter 2 inhibitor
-
Belfast, United KingdomBelfast Health and Social Care Trust
Nov 15, 2023
SGLT2-I Use in DFUD: a Delphi Study
Not yet recruiting
- Diabetic Foot Ulcer
- eDelphi method
- (no location specified)
Aug 14, 2023
Left Ventricular Remodeling in Type 2 Diabetic Acute Myocardial
Recruiting
- Myocardial Infarction
- Diabetes Mellitus, Type 2
- SGLT2 inhibitor
-
Seoul, Korea, Republic ofSeoul St. Mary's Hospital
Mar 5, 2023
SGLT-2 Inhibitors in T2DM and Moderate to Severe Liver Fibrosis
Completed
- Type2diabetes
-
New Delhi, Delhi, IndiaFortis CDOC Hospital
Jul 14, 2023
SGLT2 Inhibitors and Hemoglobin
Recruiting
- Diabetes Mellitus, Type 2
- SGLT2 inhibitor
-
Patras, GreeceUniversity Hospital of Patras
Jun 2, 2022
Diabete Type 2 Trial in El Sadat (Sitagliptin 50 mg, Empagliflozin 12.5 MG, Sitagliptin 50 mg + Empagliflozin 12.5 MG)
Completed
- Diabete Type 2
- Sitagliptin 50 mg
- +3 more
-
El Sadat, EgyptUniversity of Sadat City
Apr 27, 2022
Type2 Diabetes, Heart Failure With Preserved Ejection Fraction Trial in San Antonio (Empagliflozin 25 MG, Placebo)
Recruiting
- Type2 Diabetes
- Heart Failure With Preserved Ejection Fraction
- Empagliflozin 25 MG
- Placebo
-
San Antonio, Texas
- +1 more
Jan 21, 2023